Results 111 to 120 of about 14,439 (224)

Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis

open access: yesActa Ophthalmologica, Volume 104, Issue 8, Page 926-939, December 2026.
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car   +3 more
wiley   +1 more source

Is Australia ready for biosimilars? [PDF]

open access: yes, 2014
The biosimilars market is potentially the single fastest growing pharmaceutical sector with an estimated worth of US$67bn in global sales by 2020. This market generally refers to larger molecule, biological, protein-based pharmaceuticals which have lost
Hepworth, Julie   +2 more
core   +1 more source

Financial reimbursement incentives in the use of biosimilars for rheumatoid arthritis in Japan

open access: yesJournal of Pharmaceutical Policy and Practice
Background Biosimilars present a significant opportunity for cost savings. However, the uptake of biosimilars has been inconsistent across different regions and drugs, highlighting the need for effective policy interventions.
Hiroaki Mamiya   +2 more
doaj   +1 more source

Automated Multienzyme Digestion Workflows for Confident Characterization of Challenging Posttranslational Modifications in Therapeutic Antibodies by LC–MS/MS

open access: yesRapid Communications in Mass Spectrometry, Volume 40, Issue 21, 15 November 2026.
ABSTRACT Rationale Non‐reduced trypsin digestion of therapeutic antibodies can generate large disulfide‐linked peptide complexes that exhibit poor chromatographic and mass spectrometric performance. This limits the confident characterization of posttranslational modifications (PTMs) in specific antibody regions, such as the heavy‐chain constant region ...
Nanna Sofie Eskesen   +10 more
wiley   +1 more source

Rituximab biosimilars

open access: yes, 2015
INTRODUCTION: Rituximab is a monoclonal antibody targeting CD20, used to treat B cell malignancies and B cell-mediated autoimmune diseases. Rituximab has the largest market of any monoclonal antibody therapeutic.
Kay, Jonathan   +2 more
core   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

open access: yesAnnals of Clinical and Translational Neurology, Volume 13, Issue 11, Page 2336-2346, November 2026.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin   +11 more
wiley   +1 more source

Beyond Drugs or Surgery: Precision and Equity in Obesity Care

open access: yes
Diabetes, Obesity and Metabolism, EarlyView.
Ron T. Varghese   +4 more
wiley   +1 more source

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

open access: yesArthritis &Rheumatology, Volume 78, Issue 11, Page 2261-2273, November 2026.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher   +12 more
wiley   +1 more source

Capacity building in medicines development and regulation in Africa—Overview on recent progress

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3759-3769, November 2026.
Aims Despite advances in health research and digital innovation, many African countries continue to face substantial resource constraints, fragmented capacity‐building efforts and a shortage of skilled professionals in medicines development and regulatory science.
Tirhani Maluleke   +7 more
wiley   +1 more source

BIOLOGICALS AND BIOSIMILARS: AN OVERVIEW

open access: yes, 2018
Biologics are highly sensitive large molecules with complex structure, difficult to characterize and reproduce, derived from living cells; used for treatment, diagnosis or prevention of disease. .
K. Ravi Shankar and K.P.R. Chowdary
core   +1 more source

Home - About - Disclaimer - Privacy